Atara (ATRA) told investors its cancer therapy was on track for FDA approval. Strong data. Priority review. A major breakthrough ahead. But a new lawsuit alleges the reality was very different.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Investors who bought Atara Biotherapeutics stock during a nearly two-year window are now plaintiffs in a federal securities lawsuit alleging the company concealed serious problems with its lead product candidate while its shares were publicly traded on Nasdaq.
A complaint filed March 23, 2026, in the U.S. District Court for the Central District of California names Atara Biotherapeutics, Inc. and four current and former executives as defendants. The lawsuit alleges that the company made materially false and misleading statements about the regulatory prospects for its lead drug, tabelecleucel, while failing to disclose manufacturing deficiencies that allegedly led to the first FDA rejection, and issues with clinical trial design, conduct, and analysis that the FDA later cited in a second rejection. The class period runs from May 20, 2024, through January 9, 2026.
Investors who purchased Atara securities during that period and suffered losses may have legal rights worth exploring.
What Atara Biotherapeutics Does and Why Tabelecleucel Mattered
Atara Biotherapeutics develops therapies targeting solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product candidate, tabelecleucel, also referred to as tab-cel or EBVALLO, is a T-cell immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a serious and often fatal condition that can occur after organ or stem cell transplants.
The company’s commercialization partner for tabelecleucel is Pierre Fabre Medicament, a subsidiary of the Pierre Fabre Laboratories group. According to the complaint, Atara relied heavily on milestone payments from Pierre Fabre, financial payments tied to achieving specific developmental targets for tabelecleucel, to fund its operations. Tens of millions of dollars in milestone payments from Pierre Fabre were conditioned on FDA approval of the drug, making regulatory success central to Atara’s business and financial outlook.
What the Lawsuit Claims Atara Got Wrong
The complaint alleges that throughout the class period, Atara and its executives made repeated public statements touting the strength of the tabelecleucel BLA and the drug’s path to approval, while concealing two categories of problems: manufacturing deficiencies at a third-party contractor that were severe enough to draw FDA scrutiny, and fundamental design and conduct problems with the ALLELE clinical trial that underpinned the drug’s application. Plaintiffs allege the defendants knew or recklessly disregarded that these issues made FDA approval unlikely, yet continued to reassure investors and raise tens of millions of dollars through stock offerings in September 2024 and May 2025.
The lawsuit further alleges that the company’s Sarbanes-Oxley certifications signed by executives in multiple quarterly and annual SEC filings were false, because those filings failed to disclose the known risks threatening the BLA’s approval. The complaint identifies violations of SEC Regulation S-K Item 303, which required the company to disclose known trends or uncertainties likely to have a material unfavorable impact on revenues.
Investors who believe they suffered losses during the class period are encouraged to look into their potential legal rights.
What Executives Said to Investors
According to the complaint, Atara’s then-CEO, Pascal Touchon, stated in May 2024 that the BLA submission marked a significant moment for the company and that management looked forward to continued collaboration with the FDA and to preparing for a potential U.S. launch. In July 2024, when the FDA accepted the BLA for priority review, Touchon described the acceptance as a significant milestone and stated the company was working closely with Pierre Fabre to prepare for a potential U.S. launch in early 2025.
In November 2024, newly appointed CEO AnhCo Thieu Nguyen told investors that the first quarter of 2025 was positioned to be transformational, citing the potential for FDA approval of tabelecleucel. After the first FDA rejection in January 2025, Nguyen publicly stated the company expected approval within six months of resubmitting the application. The complaint alleges these statements, along with numerous SEC filings, were materially false and misleading at the time they were made.
How the FDA Rejections Unfolded and What Happened to the Stock
The complaint identifies three events as corrective disclosures revealing the alleged truth to investors. On January 16, 2025, Atara announced it had received a Complete Response Letter from the FDA, a notice that the drug application would not be approved in its present form, citing observations from a pre-license inspection of a third-party manufacturing facility. Atara’s stock fell $5.33 per share, or approximately 40.5%, to close at $7.83 on that date.
Five days later, on January 21, 2025, Atara disclosed that the FDA had placed a clinical hold on its active Investigational New Drug applications due to inadequately addressed manufacturing compliance issues at the same third-party facility, pausing enrollment across multiple programs, including tabelecleucel and a separate CAR-T therapy. Shares fell an additional $0.52 per share, or approximately 7.91%, to $6.05. Then, on January 12, 2026, after the company resubmitted the BLA in July 2025 and received another FDA acceptance, the agency issued a second Complete Response Letter stating the ALLELE trial was no longer considered adequate to support accelerated approval and that the trial’s interpretability was compromised by design, conduct, and analysis issues. Shares dropped $7.79 per share, or approximately 57%, to close at $5.88 on that date.
Why Shareholders Who Traded During the Class Period Should Pay Attention
The complaint alleges a pattern in which Atara raised capital from investors through stock offerings while allegedly concealing known regulatory obstacles to its most important asset. According to the complaint, Atara’s shares fell sharply across three alleged corrective disclosures: the January 16, 2025, Complete Response Letter, the January 21, 2025, clinical hold, and the January 12, 2026, second Complete Response Letter. Investors who purchased shares between May 20, 2024, and January 9, 2026, at prices the complaint alleges were artificially inflated may have recoverable losses directly tied to the alleged misstatements.
The case is significant not only for the magnitude of the stock decline but for the breadth of the alleged omissions, which the complaint says spanned manufacturing problems, clinical trial design flaws, and the financial dependence on milestone payments that gave management an incentive to maintain an optimistic public narrative. Shareholders who held or traded Atara securities during the class period should understand that a securities fraud case has been filed and that their trading history may be relevant to potential recovery.
The Legal Framework Behind the Claims
The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the SEC, which prohibit making materially false or misleading statements in connection with the purchase or sale of securities. It also asserts claims under Section 20(a) of the Exchange Act against the individual defendants as controlling persons of Atara who allegedly directed or permitted the misleading disclosures.
The plaintiff seeks to certify a class of all investors who purchased or acquired Atara securities during the class period and suffered damages upon disclosure of the alleged corrective information.
Investors who purchased Atara securities between May 20, 2024, and January 9, 2026, are encouraged to learn more about their rights and potential eligibility to participate in or lead this action.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.